ArticleThe international journal of medical robotics + computer assisted surgery : MRCAS2026
Signal Detection and Temporal Analysis of Aromatase Inhibitor-Associated Hepatotoxicity: A Pharmacovigilance Study Integrating Bayesian Belief-Propagation Network and Frequentist Metrics.
Article in The international journal of medical robotics + computer assisted surgery : MRCAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study assessed the real-world hepatotoxicity of third-generation aromatase inhibitors (AIs) for breast cancer using pharmacovigilance approaches.
methodsFAERS data (Q1 2004-Q1 2025) were analysed using a data-driven disproportionality analysis framework incorporating traditional frequentist metrics and an information-theoretic Bayesian network.
resultsA total of 24 liver-related adverse events and 7 clinical outcomes were extracted in this study. Letrozole associated with the highest number of hepatotoxicity cases and showed the highest BCPNN-supported reporting signal. Exemestane exhibited the earliest hepatotoxicity onset (median 49 days), significantly earlier (p = 0.047) than anastrozole (61.5 days) and letrozole (56 days).
conclusionAIs present distinct hepatotoxic profiles. Exemestane requires early vigilance due to its rapid onset, while letrozole exhibits the highest signal. Proactive liver monitoring and individualised management are crucial. Future research should integrate artificial intelligence with multi-modal real-world data for predictive risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.